Ranibizumab Injection

Lucentis (Ranibizumab Injection) is a prescription medication that is available in a vial form. It is a biologic medication that works by helping to stabilize the leaky blood vessels that cause vision loss in people with diabetic retinopathy.

This medication is for use in the eye and should be administered by a health care professional. It must be refrigerated at all times.

Show Filters

Showing all 2 results

Showing all 2 results

Ranibizumab Injection

Ranibizumab injection products are used to treat following occular related conditions:
1. Age-related macular degeneration that is wet (AMD). Chronic AMD is a condition of the eyes that results in loss of forward vision and can make reading, driving, and other daily tasks more challenging.

2. mCNV, or myopic choroidal neovascularization. A condition known as metacarpal vein occlusion (mCNV) affects nearsighted individuals and is used to treat macular edema following retinal vein occlusion, an eye ailment that results in impaired vision and fuzzy vision.

3. Wet age-related macular degeneration is also treated with ranibizumab implant (Susvimo) following at least two efficacious courses of treatment with ranibizumab or a comparable drug.

4. Diabetic macular edema is another eye condition that can result in visual loss and is treated with ranibizumab injection (Lucentis). Additionally, diabetic retinopathy—damage to the eyes brought on by diabetes—is treated with it.

A drug called ranibizumab is used to treat a number of eye problems, most notably retinal abnormalities and age-related macular degeneration (AMD). Usually, an injection is used to give it to the eye. The active component of some well-known medications, such as Lucentis, is ranibizumab.

How Ranibizumab works?

Ranibizumab works by attaching itself to and blocking vascular endothelial growth factor A (VEGF-A), a protein that is essential for the development of aberrant blood vessels in the eye and the flow of fluid into the retina. Ranibizumab helps lessen the development of aberrant blood vessels and the accompanying fluid leaks by inhibiting VEGF-A. The patient’s vision may then get better or remain stable as a result.

Take Care

It’s crucial to remember that ranibizumab injections usually need to be given by a medical practitioner and that they need to be monitored and treated again afterward. The exact eye ailment, the patient’s reaction to the drug, and the advice of an ophthalmologist determine how often and how long to treat the condition. Ranibizumab should only be taken under the guidance of a licensed healthcare professional due to the possibility of side effects, just like any other medication. Patients who are thinking about receiving ranibizumab therapy should talk to their doctor about the advantages and disadvantages.

Warnings and Precautions – Ranibizumab Injection

When given under the supervision of a licensed healthcare provider, ranibizumab injections are generally safe and effective. However, patients and healthcare providers should be aware of the following crucial warnings and precautions:

1. Infection Risk: Intravitreal injections, such as ranibizumab, carry a risk of infection, particularly in the eyes.

2. Elevated Eye Pressure: Some patients may have a rise in intraocular pressure (IOP) following ranibizumab injections. It’s critical to keep an eye on IOP and take proper action if it becomes elevated.

3. Thromboembolic Events: Patients on ranibizumab and other anti-VEGF drugs have been reported to experience thromboembolic events, such as heart attacks or strokes. Patients with a history of similar incidents might need to be closely watched.

4. Retinal Detachment and Tractional Retinal Detachments: Following ranibizumab injections, patients with specific eye disorders, such as tractional retinal detachments or tears, may be more susceptible to retinal detachment. Prior to giving the shots, these conditions need to be treated.

5. Hypersensitivity events: Anaphylaxis and other hypersensitivity events are possible in certain patients. Healthcare professionals should be equipped to handle these reactions in the event that they arise.

6. Hemorrhage and thrombosis: Ranibizumab may raise the risk of hemorrhage and blood clots.

Before having ranibizumab injections, patients and their doctor should have a full conversation of the advantages and disadvantages of the treatment, as well as any special safety measures or factors to take into account given the patient’s unique health and eye condition. For the best results, adherence to the prescribed treatment plan and follow-up consultations is essential.